Latest news and press releases about Zimmer Biomet Holdings, Inc. (ZBH): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific.
Price
| Price | $91.57 |
| Market Cap | $17.7B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 21.48 |
| Price / Book | 1.34 |
| EV / EBITDA | 12.33 |
| Dividend Yield | 1.09% |
Profitability
| Return on Equity | 6.36% |
| Return on Invested Capital | 5.51% |
| Return on Assets | 3.54% |
| Gross Margin | 69.87% |
| Operating Margin | 15.73% |
| Net Margin | 9.48% |
Related companies: DGX · DXCM · ILMN · INCY · LH · SNN · STE
Explore sector: Healthcare · Medical - Devices
More sections of ZBH: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks